MedTrace Logo

SARS Cov_2 Incidence of Healthy Health Workers

NCT04845880 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2021-04-15

No results posted yet for this study

Summary

Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.

Conditions

  • SARS COV-2 IgG Levels on Health Workers

Interventions

DIAGNOSTIC_TEST

Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

Sponsors & Collaborators

  • Hikmet Eda Aliskan

    collaborator UNKNOWN

  • Hatice Hale Gumus

    collaborator UNKNOWN

  • Ilker Odemis

    collaborator UNKNOWN

  • Zuhal Ekici Unsal

    collaborator UNKNOWN

  • Baskent University

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-03-01
Completion
2021-04-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04845880 on ClinicalTrials.gov